118923-32-3

Basic information

• Product Name: 5-BENZO[1,3]DIOXOL-5-YL-2H-TETRAZOLE
• Synonyms: BUTTPARK 51\03-54;ART-CHEM-BB B020649;5-BENZO[1,3]DIOXOL-5-YL-2H-TETRAZOLE;5-(1,3-BENZODIOXOL-5-YL)-2H-TETRAZOLE;AKOS B020649;SALOR-INT L307831-1EA
• CAS NO: 118923-32-3
• Molecular Formula: C₈H₆N₄O₂
• Molecular Weight: 190.16
• Mol File: 118923-32-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BENZO[1,3]DIOXOL-5-YL-2H-TETRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BENZO[1,3]DIOXOL-5-YL-2H-TETRAZOLE(118923-32-3)
• EPA Substance Registry System: 5-BENZO[1,3]DIOXOL-5-YL-2H-TETRAZOLE(118923-32-3)

Safety Data

• Hazardous Substances Data: 118923-32-3(Hazardous Substances Data)

Upstream product

• 4421-09-4 piperonylonitrile 
• 120-57-0 piperonal 
• 2089-36-3 (E)-3,4-methylenedioxybenzaldehyde oxime 
• 5876-51-7 5-iodo-1,3-benzodioxole 
• 2089-36-3 piperonal oxime 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 

Downstream Products

• 1358577-80-6 5-(1,3-benzodioxol-5-yl)-1-[(4-isopropylphenyl)sulfonyl]-1H-tetrazole 
• 1358577-77-1 5-(1,3-benzodioxol-5-yl)-1-[(2,4-dichlorophenyl)sulfonyl]-1H-tetrazole 
• 1358577-71-5 5-(1,3-benzodioxol-5-yl)-1-[(4-chlorophenyl)sulfonyl]-1H-tetrazole 
• 1358577-67-9 5-(1,3-benzodioxol-5-yl)-1-(phenylsulfonyl)-1H-tetrazole 
• 1358577-69-1 5-(1,3-benzodioxol-5-yl)-1-[(4-methylphenyl)sulfonyl]-1H-tetrazole 
• 1358577-75-9 5-(1,3-benzodioxol-5-yl)-1-[(4-nitrophenyl)sulfonyl]-1H-tetrazole 
• 1604821-55-7 (R)-2-(2-(5-(benzo[d][1,3]dioxol-5-yl)-2H-tetrazol-2-yl)-N-cyclohexylacetamido)-N-cyclopentylpropanamide 

Relevant articles and documents

Synthesis, characterization and anticancer screening of some novel piperonyl-tetrazole derivatives

A series of new 1,2-substituted tetrazole derivatives were synthesized and evaluated on MCF-7 (ER positive), MDA-MB-231 and ZR-75 (ER negative) breast cancer cell lines. Out of the fourteen compounds, three compounds 10, 12 and 14 showed higher inhibitory effects on MCF-7 cells. Whereas, compound 8 exhibited higher inhibition in MDA-MB-231 and ZR-75 cells at 10-5 M concentration. Total RNA was extracted and effect of compounds on different marker genes was studied. The gene expression of CD44, BRAC and BAX were significantly affected. The compounds were screened against the HepG2 cell line, to know if they are selectively targeting specific cancers and only 1-10 percent inhibition was found at 10-5 M concentration.

NOVEL TETRAZOLO HYDRAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER

Provided are novel tetrazolo hydrazone derivatives or pharmaceutically acceptable salts thereof. The derivatives and the salts may inhibit the proliferation of cancer cells in a low molar concentration and inhibit the activity of cancer cells through the regulation of expression of apoptosis-related genes or the like, thus expressing excellent anti-cancer activity, and therefore, can be used effectively in preventing or treating cancer.

HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BL

This appl ication describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, wh ich compounds and methods can be used, for example, to med iate h igh-density l ipoprotein (H DL) l ipid uptake and treat hepatitis C vira l infections. The compounds have the formu la : wherein R1 and R2 are independently H, halogen, cyano, haloalkyl, ha loa lkyloxy or OMe; or R1 and R2 together are -O-CH2-O- or -0- CF2-O-; R3 is H, ha logen, cyano, ha loalkyl or ha loa lkyloxy; R4 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl or C3-6cycloheteroalkyl, wherein the heteroatom is N or 0; R5 is H or CH3; R6 is C1-6alkyl or C3-6cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.